Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 27;3(4):100316.
doi: 10.1016/j.jacig.2024.100316. eCollection 2024 Nov.

MASTering systemic mastocytosis: Lessons learned from a large patient cohort

Kevin Y Tse  1 , Wansu Chen  2 , Eric J Puttock  2 , Shanta Chowdhury  2 , Kerri Miller  3 , Dakota Powell  3 , Benjamin Lampson  3 , Chris Yuen  3 , Doug Cattie  3 , Teresa Green  3 , Erin Sullivan  3 , Robert S Zeiger  1   2   4
Affiliations

MASTering systemic mastocytosis: Lessons learned from a large patient cohort

Kevin Y Tse et al. J Allergy Clin Immunol Glob. .

Abstract

Background: Systemic mastocytosis (SM), a rare condition affecting about 32,000 individuals in the United States, is often misdiagnosed or underdiagnosed owing to its nonspecific symptoms and the need for invasive biopsies.

Objective: Our aim was to identify, classify, and characterize the natural history of patients with SM.

Methods: In a retrospective cohort study, administrative data from a large managed care organization was used to identify patients with confirmed SM, based on World Health Organization criteria. Demographic data, delay to diagnosis, disease progression, and health care resource utilization were examined.

Results: Of 116 patients with confirmed SM, 77% had indolent SM, 2% had smoldering SM, 12% had SM with associated hematologic neoplasm, 9% had aggressive SM, and none had mast cell leukemia. In all, 5 patients were misclassified as having a less advanced SM subtype initially and 3 were completely undiagnosed (missed diagnosis). The average delay to diagnosis of SM was 58.3 plus or minus 73.1 months. In all, 18% of patients progressed from a nonadvanced form of SM (indolent or smoldering SM) to an advanced form of SM (aggressive SM, SM with associated hematologic neoplasm, or mast cell leukemia) over an average of 88.3 plus or minus 82.7 months. Patients with SM had increased health care utilization, including increases in their numbers of hospital admissions, emergency room visits, urgent care visits, and specialty provider visits, after diagnosis versus before.

Conclusions: Rare diseases such as SM would benefit from increased understanding and awareness to improve diagnostic accuracy. Prospective studies are needed to better characterize this patient population and determine the type of follow-up needed to recognize advanced forms of SM so that appropriate treatment can be implemented.

Keywords: Mastocytosis; diagnostic delay; health care utilization; mortality; progression.

PubMed Disclaimer

Conflict of interest statement

Supported by Blueprint Medicines (Cambridge, Mass) through an unrestricted grant to Kaiser Permanente Southern California, as well as by the National Heart, Lung and Blood Institute (grant to R.S.Z.) Disclosure of potential conflict of interest: for Kaiser Permanente Southern California: R. S. Zeiger has received grants from Aerocrine, 10.13039/100004328Genentech, 10.13039/501100004628MedImmune/10.13039/100004325AstraZeneca, Merck, 10.13039/100004330GlaxoSmithKline, Teva, and Quest; has warrants from DBV Technologies; and has provided consultant activity for AstraZeneca, Bayer, Regeneron/Sanofi, Merck, and Genentech/Novartis. K. Miller, D. Powell, B. Lampson, C. Yuen, D. Cattie, T. Green, and E. Sullivan are employed by Blueprint Medicines. The rest of the authors declare that they have no relevant conflicts of interest.

Figures

Fig 1
Fig 1
A, Kaplan-Meier curve for SM progression from nonadvanced SM to any advanced SM. Nonadvanced SM includes ISM and SSM, whereas advanced SM includes SM-AHN, ASM, and MCL. B, Kaplan-Meier curve for death from SM diagnosis to death.
See this image and copyright information in PMC

References

    1. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014;34:283–295. - PubMed
    1. Mesa R.A., Sullivan E.M., Dubinski D., Carroll B., Slee V.M., Jennings S.V., et al. Perceptions of patient disease burden and management approaches in systemic mastocytosis: results of the TouchStone Healthcare Provider Survey. Cancer. 2022;128:3700–3708. - PMC - PubMed
    1. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. - PubMed
    1. Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019;94:363–377. - PubMed
    1. Leguit R.J., Wang S.A., George T.I., Tzankov A., Orazi A. The international consensus classification of mastocytosis and related entities. Virchows Arch. 2023;482:99–112. - PubMed

LinkOut - more resources